⚡ Flash Summary

Ferozsons Laboratories Limited held its 69th Annual General Meeting on October 25, 2025, where several resolutions were passed. Key decisions included confirming the minutes of the previous AGM, adopting the audited financial statements for the year ended June 30, 2025, and approving a final cash dividend of 40% (Rs. 4 per share). Auditors for the year ending June 30, 2026, were appointed. The meeting also ratified related party transactions conducted during the financial year 2024-25 and authorized the Board of Directors to approve future related party transactions.

📌 Key Takeaways

• ✅ Minutes from the Annual General Meeting held on October 28, 2024, were confirmed.
• 👍 Audited financial statements for the year ending June 30, 2025, were adopted.
• 💰 A final cash dividend of 40% (Rs. 4 per share) for the year ending June 30, 2025, was approved.
• 🤝 KPMG Taseer Hadi & Co. re-appointed as external auditors for the year ending June 30, 2026.
• 💼 Board of Directors authorized to fix the remuneration of the auditors.
• 🤝 Related party transactions for the financial year 2024-25 were ratified.
• ✅ Board authorized to approve all future related party transactions.
• 📜 Resolutions passed were extracted and certified as true copies.
• 🗓️ The announcements pertain to decisions made in the AGM held on October 25, 2025.
• 🏢 The company has multiple locations including a Head Office/Biotech Factory, Registered Office, Pharma Factory, and Sales Offices in Lahore and Karachi.
• 🌐 Information available via email and website (info@ferozsons-labs.com & www.ferozsons-labs.com).

🎯 Investment Thesis

Based on the dividend announcement and auditor reappointment, a HOLD recommendation is appropriate. The dividend signals a commitment to shareholder returns, but further analysis of the company’s financial statements is needed to assess long-term growth potential. Price target: To be determined based on detailed financial analysis. Time horizon: Medium-term (6-12 months), pending release and analysis of full financial statements.